ESMO mini oral data presented. mOS in PD>1% now 35.5 months (previously reported 25 months), in the PD >50% category mOS not reached! (previously 38 months reported, maybe expect +50 months if i understood the table correctly).
Data highly promising, looking kickass against a ph3 comparison arm against Ipi+Nivo+chemo.
Has Eftilagimod shown enough potential to warrant a commercialisation deal?
ESMO mini oral data presented. mOS in PD>1% now 35.5 months...
-
- There are more pages in this discussion • 616 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54900 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 22008 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |